Immuneering Corporation
IMRX
$6.74
$0.050.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.63% | -10.81% | -14.03% | -14.15% | -12.46% |
| Total Depreciation and Amortization | -6.35% | -1.03% | 3.91% | 9.34% | -54.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.71% | 18.96% | 30.24% | 28.33% | 45.81% |
| Change in Net Operating Assets | 840.72% | 492.55% | 154.60% | 5.05% | 69.24% |
| Cash from Operations | 4.30% | -1.36% | -7.09% | -12.32% | -6.79% |
| Capital Expenditure | 88.76% | 91.38% | 83.99% | 75.20% | -2.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.39% | -98.46% | -49.45% | 247.15% | 93.71% |
| Cash from Investing | -77.27% | -98.84% | -48.20% | 262.30% | 95.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4,200.32% | 1,709.90% | -37.85% | -81.04% | -81.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 37.49% | 37.49% | 100.00% |
| Cash from Financing | 4,139.29% | 1,690.92% | -37.86% | -81.35% | -81.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 898.60% | 24.65% | -173.01% | -75.81% | -172.57% |